Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction.

ABSTRACT:

Aims

The DELIVER study demonstrates a significant improvement in cardiovascular death or hospitalization for heart failure among heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF).Cost-utility of the adjunct use of dapagliflozin to standard therapy among patients with HFpEF or HFmrEF remains unclear.

Methods and results

A five-state Markov mode was constructed to project health and clinical outcomes of the adjunct use of dapagliflozin to standard therapy among 65-year-old patients with HFpEF or HFmrEF. A cost-utility analysis was performed based on the DELIVER study and national statistical database. The cost and utility was inflated to 2022 by the usual discount rate of 5%. The primary outcomes were total c

SUBMITTER: Tang Y 

PROVIDER: S-EPMC10375078 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature